个人简介

Dr. Susan Dorman is a professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include infectious diseases. Dr. Dorman received her undergraduate degree in biochemistry from Trinity College. She earned her M.D. from Duke University School of Medicine. She completed her residency at Brigham and Women’s Hospital and performed a fellowship in infectious diseases at the National Institutes of Health (NIH). Prior to joining Johns Hopkins in 2001, Dr. Dorman held several positions with the NIH Laboratory of Host Defenses. Dr. Dorman’s research focuses on the development and evaluation of new diagnostic tests for tuberculosis. MD, Duke University School of Medicine (1993)

研究领域

Tuberculosis

The focus of Dr. Dorman’s work is the development and evaluation of new diagnostic tests for tuberculosis (TB). There is an urgent need for sensitive, specific, rapid tests for detection of active TB disease, latent TB infection and M. tuberculosis drug resistance. Her lab’s TB diagnostics work involves both laboratory and clinical research, and they have active collaborations with investigators in Brazil and Honduras. The other major focus of her work is the investigation of immunologic and genetic factors that affect susceptibility to M. tuberculosis.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, Barnes GL, Hoffman J, Chaisson RE, McIlleron H5, Dorman SE. "Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis." Int J Tuberc Lung Dis. 2015 Jul;19(7):780-6. doi: 10.5588/ijtld.14.0868. Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW, ACTG A5311 Study Team. "Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers." Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30. Dorman S. "Advances in the diagnosis of tuberculosis: current status and future prospects." Int J Tuberc Lung Dis. 2015 May;19(5):504-16. doi: 10.5588/ijtld.15.0048. Fielding KL, Charalambous S, Hoffmann CJ, Johnson S, Tlali M, Dorman SE, Vassall A, Churchyard GJ, Grant AD. "Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial." Trials. 2015 Mar 28;16:125. doi: 10.1186/s13063-015-0650-0. Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium. "Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial." Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC.